marijuana stock news

Insys Therapeutics to Present at Jefferies 2015 Healthcare Conference

Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery systems, today announced that Michael L. Babich, President and Chief Executive Officer, and Darryl Baker, Chief Financial Officer, will present at the Jefferies 2015 Healthcare Conference as follows:

Conference: Tuesday, June 2, 2015
Time: 11:00 a.m. EDT

The presentation will be webcast live at the aforementioned time as well as archived for 90 days thereafter, via the Company’s website at www.insysrx.com, under the Investors Section.

About Insys Therapeutics, Inc.
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using our proprietary sublingual spray technology and our capability to develop pharmaceutical cannabinoids, Insys addresses the clinical shortcomings of existing commercial products. Insys currently markets two products, Subsys®, which is sublingual Fentanyl spray for breakthrough cancer pain, and a generic version of Dronabinol (THC) capsules. The Company’s lead product candidate is Dronabinol Oral Solution, a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is developing a pipeline of sublingual sprays, as well as pharmaceutical cannabidiol.

Subsys® is a registered trademark of Insys Therapeutics, Inc.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie Inc. (ABBV) to Host First-Quarter 2023 Earnings Conference Call

AbbVie to Host First-Quarter 2023 Earnings Conference Call AbbVie (NYSE: ABBV) will…

Better Choice Company Inc. (BTTR) to Announce Fourth Quarter and Full Year 2022 Financial Results

Better Choice to Announce Fourth Quarter and Full Year 2022 Financial Results…

1933 Industries Inc. (TGIF) (TGIFF) Executes Licensing Agreement with PLUGplay

1933 Industries Executes Licensing Agreement with PLUGplay and Prepares for Nevada-Wide Launch…

$OXIS Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer

Oxis Biotech Licenses Rights To Antibody-Drug Conjugates For The Treatment Of Cancer…